Medirom Appeals Nasdaq Delisting, Wins 15-Day Trading Stay After Filing Overdue 20-F
MRM is trading near its 52-week low of $0.245 (3.1% above the low) on elevated volume (3.3× avg).
Summary
Medirom filed its overdue FY2025 20-F and appealed its November 13 Nasdaq delisting determination, which automatically stays any trading suspension for 15 days. The separate sub-$1.00 bid price deficiency remains unresolved.
Key Events · Legal and Risk Events · MRM
-
Nasdaq Delisting Determination Received
On November 13, 2026 Nasdaq notified Medirom it had not regained compliance with Listing Rule 5250(c)(1) because the FY2025 20-F was not filed within the granted extension; absent an appeal, ADS trading would be suspended and delisted at the open on November 24, 2026.
-
Hearing Request Stays Suspension 15 Days
The company submitted a hearing request before a Nasdaq Hearings Panel on November 18, 2026, which automatically stays any trading suspension for 15 days from the request date; Medirom has also asked for an extended stay through the hearing process.
-
Overdue 20-F Filed Same Day
The FY2025 Annual Report was filed with the SEC on November 18, 2026 and presented to Nasdaq in support of the appeal; Nasdaq has not yet said whether the filing resolves the periodic reporting deficiency.
-
Bid Price Deficiency Still Open
The October 6, 2026 notice for failing the $1.00 minimum bid price rule under Listing Rule 5550(a)(2) is separate and unresolved by the 20-F filing; Nasdaq gave the company until April 5, 2027 to regain compliance, with the stock at $0.2525.
Analysis · MRM · Trade & Services
The delisting determination Medirom received on November 13 would have suspended its ADSs at the open on November 24, but the company has bought itself time on two fronts. Filing the overdue FY2025 20-F on November 18 cures the underlying reporting deficiency, and the hearing request submitted the same day automatically blocks any suspension for 15 days while the company seeks a longer stay. That is time, not a reprieve: the Panel has full discretion, and the separate $1.00 minimum bid deficiency — with a deadline of April 5, 2027 — is untouched by the annual report. With the stock at $0.2525 against a $1.00 bid requirement, a reverse split or further equity action is the likely path, and the 20-F itself carries going-concern doubt and a JPY3.6 billion net loss.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRM was trading at $0.25 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.25 to $2.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.